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OBJECTIVES We sought to compare outcomes between patients with acute myocardial infarction (AMI)
undergoing percutaneous transluminal coronary angioplasty (PTCA) with an optimal or
“stent-like” result versus patients who underwent routine stent placement.
BACKGROUND Recent studies in patients with AMI undergoing stent implantation have suggested that
PTCA may no longer be a relevant treatment modality for stent eligible lesions. However,
whether routine stent placement is superior or necessary when an optimal PTCA or
“stent-like” result is achieved is unknown.
METHODS In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Compli-
cations (CADILLAC) trial, 2,082 patients with AMI were randomly assigned to undergo
PTCA alone, PTCA  abciximab, stenting alone, or stenting  abciximab. Outcomes were
compared in patients achieving an optimal acute PTCA result (residual core laboratory
diameter stenosis 30% without significant dissection) versus those assigned to routine
stenting.
RESULTS Optimal PTCA was achieved in 40.7% of patients randomized to balloon angioplasty,
including 38.5% and 42.7% assigned to PTCA alone and PTCA  abciximab, respectively.
Ischemic target vessel revascularization (TVR) at 30 days occurred more frequently after
optimal PTCA than routine stenting (5.1% vs. 2.3%, p  0.007). The one-year composite
adverse event rate (death, reinfarction, disabling stroke, or TVR) was greater after optimal
PTCA than routine stenting (21.9% vs. 13.8%, p  0.001), driven largely by increased rates
of ischemic TVR (19.1% vs. 9.1%, p  0.001); no significant differences were present in the
rates of death, reinfarction, or disabling stroke between the two groups. Angiographic
restenosis also was more common with optimal PTCA than routine stenting (36.2% vs.
22.2%, p  0.003). Even a post-PTCA diameter stenosis of 20% (realized in 12% of
patients) did not result in outcomes equivalent to stenting.
CONCLUSIONS Even if an optimal result is achieved after primary PTCA in AMI, early and late outcomes
can be further improved with routine stent implantation. (J Am Coll Cardiol 2003;42:
971–7) © 2003 by the American College of Cardiology Foundation
The reduction in restenosis after coronary stent implanta-
tion compared with percutaneous transluminal coronary
balloon angioplasty (PTCA) has been attributed to the
ability of the stent to achieve a larger immediate post-
procedure minimal luminal diameter (1–3). Some (4–9),
but not all (10–14) studies of elective percutaneous coronary
intervention (PCI) have demonstrated equivalent long-term
outcomes in patients achieving an optimal or “stent-like”
PTCA result compared with a strategy of routine stent
implantation, which may result in reduced health care
resource consumption and medical costs (15–18). As the
See page 978
underlying culprit plaque in acute myocardial infarction
(AMI) is typically soft and modest in severity (19–23),
PTCA in this setting might be expected to more frequently
result in an optimal result with a lower residual stenosis
compared to intervention in patients with stable angina.
However, whether the early and late outcomes in AMI
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patients achieving an optimal PTCA result are comparable
to those undergoing routine stent implantation is unknown.
The Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC)
trial was a large-scale multicenter, prospective, randomized
trial designed to determine the optimal reperfusion strategy
in patients with evolving AMI (24). The purpose of this
present analysis is to determine the frequency of achieving
an optimal PTCA result in AMI, and whether the long-
term outcomes after optimal PTCA are similar and cost-
effective compared with a routine stent strategy.
METHODS
Study population and study protocol. The details of the
CADILLAC protocol have been previously reported (24).
In brief, 2,082 patients of any age with AMI within 12 h of
symptom onset at 82 international centers were randomized
to undergo PTCA alone, PTCA  abciximab, stenting
alone with the MultiLink or MultiLink Duet stent
(Guidant, Santa Clara, California), or stenting  abcix-
imab. Patients with cardiogenic shock, current administra-
tion of thrombolytic therapy, stroke within two years, or any
permanent residual neurologic defect were excluded. All
patients provided written informed consent before
enrollment.
Catheterization procedure and concomitant medications.
Patients received 324 mg of chewable aspirin, ticlopidine
500 mg or clopidogrel 300 mg, a 5,000-U heparin bolus,
and intravenous beta-blockade in the absence of contrain-
dications before catheterization. Left ventriculography and
arteriography were performed with ioxoaglate, with ran-
domization of consecutive patients meeting angiographic
enrollment criteria (native coronary artery infarct vessel with
estimated lesion length64 mm and reference diameter 2.5
to 4.0 mm).
Among patients randomized to PTCA (with or without
abciximab), crossover to stenting (bail-out) was permitted
for a visually estimated residual stenosis of 50% or
dissection  National Heart, Lung, and Blood Institute
(NHLBI) type C. However, before stent implantation in
PTCA assigned patients, prolonged balloon inflations of at
least 5 min were mandated (with an autoperfusion balloon
recommended), as was the use of slightly oversized balloons.
Data collection, definitions, and statistical analysis.
Independent study monitors verified 100% of case report
form data on-site, and all primary end point events were
adjudicated by an independent committee blinded to ran-
domization allocation. Core laboratory angiographic analy-
sis was performed as previously described (25). Follow-up
angiography at seven months was completed in 656 (72.9%)
of 900 pre-specified eligible patients and was evaluable in
628 patients.
The primary end point was a composite of death from any
cause, reinfarction, repeated percutaneous intervention or
surgical revascularization of the target vessel as a result of
ischemia, or disabling stroke. For the present analysis, an
optimal or “stent-like” PTCA result was defined as a
residual core angiographic laboratory-determined diameter
stenosis 30% with dissection  NHLBI type A and final
Thrombolyis In Myocardial Infarction (TIMI) grade 3 flow
obtained by balloon angioplasty only, a definition similar to
that employed in previous analyses of optimal PTCA results
(4). Other definitions were as previously described (24).
Procedural and clinical outcomes of patients achieving
optimal PTCA were compared with those of all patients
assigned to stenting.
For the economic analysis, medical care costs were
assessed for all U.S. patients in the study cohort using
Table 1. Demographic Features and Procedural Outcomes
Optimal
PTCA
(n  415)
Stent
(n  1,036) p Value
Age (yrs) 61 (52–69)* 59 (51–68) 0.23
Age 70 yrs 19.8% 20.7% 0.70
Male gender 74.7% 73.3% 0.60
Current smoker 40.0% 43.5% 0.24
Diabetes mellitus 18.3% 17.8% 0.82
Hypertension 48.0% 47.9% 1.00
Hypercholesterolemia 37.6% 37.5% 1.00
Prior myocardial infarction 14.9% 12.5% 0.23
Index LVEF % (operator
defined)
50 (40–58) 50 (40–58) 0.86
Multivessel disease 45.8% 49.6% 0.20
Killip class I 87.4% 88.7% 0.53
ST-segment elevation
or LBBB
85.1% 87.6% 0.25
Symptom onset to ER
arrival (h)
1.8 (1.0–3.0) 1.9 (1.0–3.6) 0.27
ER arrival to balloon
inflation (h)
2.0 (1.5–2.8) 2.0 (1.5–2.7) 0.81
Infarct-related artery
Left anterior descending 37.6% 36.1% 0.63
Left circumflex 20.5% 18.3% 0.37
Right 41.9% 45.6% 0.22
Abciximab administered 53.3% 52.6% 0.86
Maximal device size (mm) 3.3 (3.0–3.5) 3.5 (3.0–3.5) 0.02
Maximal pressure (atm) 9 (8–12) 14 (13–16) 0.0001
*Data are presented as median, with interquartile range in parentheses.
ER  emergency room; LBBB  left bundle-branch block; LVEF  left
ventricular ejection fraction; PTCA  percutaneous transluminal coronary angio-
plasty.
Abbreviations and Acronyms
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complications
NHLBI  National Heart, Lung, and Blood
Institute
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
TIMI  Thrombolysis In Myocardial Infarction
TVR  target vessel revascularization
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previously described methodology (17). Detailed resource
utilization data were recorded for all revascularization pro-
cedures, and procedural costs were based on measured
resource utilization and 2001 unit costs. Non-procedural
hospital costs were estimated by converting hospital charges
to costs according to hospital and cost-center specific
cost-to-charge ratios. Costs for inpatient and outpatient
physician services were calculated using the 2001 Medicare
fee schedule for Massachusetts. Stent- and abciximab-
related costs from the index procedure were included in the
economic formulas. All repeat revascularization procedures
were reviewed by an independent clinical events committee
blinded to treatment assignment to determine whether they
were prompted by symptoms, ischemia, or protocol-driven
angiography. In the patient cohort assigned to follow-up
angiography, repeat cardiac catheterization, associated hos-
pital costs, and any related revascularization procedures that
were judged to have been protocol-induced rather than
clinically driven were excluded from the economic analysis.
The incremental cost-effectiveness ratio for stenting com-
pared with optimal PTCA was calculated by dividing the
mean one-year cost difference by the difference in one-year
repeat revascularization rates between the two groups, as
previously described (17,26).
Categorical variables were compared by Fisher exact test.
Continuous variables are presented as median (interquartile
range) or mean standard deviation and were compared by
the Wilcoxon two-sample test. Time to event data were
displayed as Kaplan-Meier curves and compared by the
log-rank test. All analyses were by intention to treat, and all
p values are two-sided. Significance was established at p 
0.05. Adjustments for multiple comparisons were not per-
formed.
RESULTS
Patient population and baseline characteristics. A total
of 1,046 patients were randomized to PTCA with or
without abciximab, 168 (16%) of whom required a stent for
unacceptable results. Of the remaining 878 patients, core
laboratory angiographic analysis was complete in 855, 415
of whom had an optimal PTCA result. Optimal PTCA was
thus achieved in 415 (40.7%) of 1,023 evaluable PTCA
patients, including 38.5% and 42.7% assigned to PTCA
alone and PTCA  abciximab, respectively (p  0.17).
Patients in whom optimal PTCA was achieved and those
assigned to routine stent implantation were well-matched
with respect to baseline clinical characteristics (Table 1). Stents
were implanted in 97.9% of patients assigned to stenting, and
by definition in 0% of optimal PTCA patients. Infarct artery
distribution and abciximab use were similar in the two groups
(Table 1). Maximum device size and maximum balloon pres-
sures were higher in the routine stent group.
Angiographic results. Core laboratory angiographic anal-
ysis appears in Table 2. The TIMI-3 flow rates were similar
at baseline. By definition, all patients with optimal PTCA
Table 2. Core Laboratory Angiographic Analysis
Optimal PTCA
(n  415)
Stent
(n  1,036) p Value
TIMI flow pre
0–1 66.0% 67.0% 0.72
2 9.7% 10.3% 0.77
3 24.3% 22.7% 0.54
TIMI flow final
0–1 0% 1.5% 0.008
2 0% 2.8%  0.0001
3 100% 95.7%  0.0001
Angiographic subset
n 130 325
Reference diameter pre (mm) 2.8 (2.6–3.2)* 3.0 (2.6–3.3)  0.001
Minimal luminal diameter pre (mm) 0 (0–0.7) 0 (0–0.8) 0.62
Minimal luminal diameter post (mm) 2.2 (2.0–2.5) 2.4 (2.1–2.7)  0.001
Minimal luminal diameter at 7 months (mm) 1.6 (1.2–2.1) 2.0 (1.6–2.4)  0.001
Diameter stenosis pre (%) 100 100 0.53
Diameter stenosis post (%) 22.2 11.9  0.0001
Diameter stenosis at 7 months (%) 39.0 29.5  0.0001
Restenosis (%) 36.2 22.2 0.003
Infarct artery reocclusion (%) 10.0 5.8 0.15
Left ventricular ejection fraction (%)
Index procedure 56.83 (48.08–63.65) 55.99 (46.99–63.80) 0.35
Follow-up 61.48 (53.87–68.66) 60.14 (51.56–68.70) 0.28
Infarct zone regional wall motion (SD/chord)
Index procedure 1.22 (1.61 to 0.84) 1.34 (1.67 to 0.82) 0.13
Follow-up 0.77 (1.23 to 0.33) 0.80 (1.30 to 0.32) 0.63
*Data are expressed as median, with interquartile range in parentheses.
PTCA  percutaneous transluminal coronary angioplasty; SD  standard deviation; TIMI  Thrombolysis In Myocardial
Infarction.
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achieved TIMI-3 flow compared to 95.7% of routine stent
patients. Despite similar baseline quantitative measures,
patients assigned to stenting had a significantly lower
diameter stenosis post procedure and at follow-up, with a
correspondingly marked reduction in binary angiographic
restenosis. Myocardial recovery and infarct artery reocclu-
sion were similar in both groups.
Clinical outcomes. At 30 days, no differences were noted
between optimal PTCA and routine stenting with respect to
the primary composite end point of death, reinfarction,
ischemic target vessel revascularization (TVR), or disabling
stroke (Table 3). The individual 30-day rates of mortality,
disabling stroke, reinfarction, and subacute thrombosis were
also comparable between the two groups, though recurrent
ischemia necessitating repeat TVR was twice as common
after optimal PTCA compared with routine stent implan-
tation (Table 3). An optimal PTCA result did not provide
freedom from subacute thrombosis.
At one year, event-free survival was significantly greater
in patients assigned to routine stenting than in those
achieving optimal PTCA, driven primarily by greater free-
dom from ischemic TVR in patients randomized to stenting
(Table 3). Rates of death, disabling stroke, and reinfarction
were similar among the two groups. Early and late outcomes
among patients achieving optimal PTCA were unaffected
by abciximab randomization (Fig. 1).
The results of optimal PTCA were inferior to those of
routine stent implantation for most relevant clinical and
angiographic subgroups examined, except in very large
vessels (Fig. 2); no patient or lesion subsets were identified
in which the late outcomes of optimal PTCA were superior
to stent implantation. Notably, restricting the definition of
optimal PTCA to require a core laboratory diameter steno-
sis20% (present in 12.3% of patients) did not significantly
improve the absolute or relative late prognosis compared
with routine stenting (Fig. 2).
Economic analysis. Routine stenting increased hospital
costs by a mean of $2,519 per patient (Table 4). Over one
year, stent patients required significantly fewer hospital
admissions, hospital days, and repeat revascularization pro-
cedures. As a result, follow-up costs were a mean of $1,635
less per patient in the routine stent group, resulting in
aggregate one-year costs that were $883 higher in the stent
group (p  0.20). The mean cost-effectiveness ratio for
routine stenting versus optimal PTCA was thus $6,104 per
repeat revascularization procedure avoided.
DISCUSSION
Routine stent implantation in patients undergoing mechan-
ical reperfusion therapy for AMI has been clearly shown to
result in reduced rates of angiographic restenosis and sub-
sequent need for TVR (24,27–33). However, stent implan-
tation may occasionally have undesirable consequences,
including “jailing” of side branches and refractory in-stent
restenosis (34–38). Furthermore, the additional catheteriza-
Table 3. Early and Late Clinical Outcomes
Optimal PTCA
(n  415)
Stent
(n  1,036) p Value
30-day event rates (%)
Composite end point 6.8 5.0 0.20
Death 1.7 2.4 0.39
Disabling stroke 0 0.2 0.37
Reinfarction 0.2 0.9 0.19
Ischemic target vessel
revascularization
5.1 2.3 0.007
Subacute thrombosis 1.0 0.5 0.29
1-year event rates (%)
Composite end point 21.9 13.8 0.0002
Death 3.2 4.2 0.28
Disabling stroke 0.3 0.7 0.31
Reinfarction 2.2 2.2 0.99
Ischemic target vessel
revascularization
19.1 9.1 0.0001
Composite end point  death, disabling stroke, reinfarction, or ischemic target vessel
revascularization; PTCA  percutaneous transluminal coronary angioplasty.
Figure 1. Individual and composite adverse event rates at 30 days (upper
graph) and 1 year (lower graph) in patients achieving optimal percutane-
ous transluminal coronary angioplasty (PTCA) results randomized to
pre-procedural abciximab administration (white bars) versus no pre-
procedural abciximab. The p values for all two-way comparisons in both
graphs are non-significant. TVR  target vessel revascularization.
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tion laboratory and index hospitalization costs of routine
stent use are not trivial (17). For these reasons, a “balloon
only” approach might be desirable in selected patients. In
the large multicenter CADILLAC trial, however, stenting
compared with PTCA by intention to treat analysis resulted
in improved outcomes in all examined pre-specified clinical
subsets (24). Whether the early and late outcomes of
patients achieving optimal or “stent-like” PTCA are equiv-
alent to those undergoing routine stenting (in accordance
with the “bigger is better” dictum [39,40]) has not been
comprehensively examined in an AMI population, though
studies in the elective setting have suggested that such a
strategy may have merit (4–9).
The principal finding of the present analysis is that even
the achievement of an optimal PTCA result during primary
PCI for AMI, as defined by strict quantitative core labora-
tory criteria, did not result in equivalent outcomes compared
with a routine stent strategy. Of note, using contemporary
techniques (including prolonged balloon inflations and the
luxury of balloon oversizing afforded by the availability of
stents to manage severe dissection), an optimal PTCA result
could be realized in a relatively large percentage (40.7%) of
Figure 2. Subgroup analysis for the one-year composite end point of death, disabling stroke, reinfarction, or ischemic target vessel revascularization,
comparing patients achieving an optimal percutaneous transluminal coronary angioplasty (PTCA) result (n  415) with all patients randomized to stent
implantation (n  1,036), displayed as hazard ratios (black boxes) with 95% confidence intervals (CI) (horizontal limit lines). OR  odds ratio.
Table 4. Economic Analysis
Optimal PTCA
(n  329)
Stent
(n  846) p Value
Index PCI cost $3,014  846* $4,652  1,283  0.0001
Total index length of stay (days) 4.76  2.16 5.17  3.42 0.04
Total index hospital costs $11,386  4,537 $13,905  5,506  0.0001
Repeat hospitalization (%) 66 48 0.001
Rehospitalization days (n per 100 patients) 238  447 184  418 0.05
Patients with repeat revascularization (%) 26 18 0.001
Total follow-up costs discharge to one year $6,589  10,173 $4,954  8,106 0.004
Total one-year costs $17,976  11,416 $18,859  10,280 0.200
*Data are expressed as mean  SD.
PCI  percutaneous coronary intervention; PTCA  percutaneous transluminal coronary angioplasty.
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PTCA patients in this trial. However, even those patients in
CADILLAC with optimal acute PTCA results did not
have equivalent short- and long-term outcomes compared
with stenting; optimal PTCA patients still had higher rates
of recurrent ischemia necessitating TVR at 30 days, and late
restenosis necessitating TVR between 30 days and one year,
independent of randomization to abciximab. Optimal
PTCA did not match the late results of routine stenting
even when a post-PTCA diameter stenosis 20% by
quantitative angiography was achieved (equivalent to a
visually estimated residual stenosis of 0% to 10%). Eco-
nomic analysis demonstrated acceptable cost-effectiveness
for routine stenting compared with optimal PTCA. Thus,
routine stent placement should be the default therapy in
primary PCI for AMI in most patients.
The relative benefits of a routine stent strategy compared
with optimal PTCA were independent of gender, diabetes,
and lesion length and were present in young patients,
intermediate diameter vessels, and left circumflex and right
coronary artery infarcts. Trends were also present for im-
proved outcomes of routine stenting compared with optimal
PTCA in the elderly, small vessels, and in infarcts involving
the left anterior descending artery. Only in large vessels
(reference vessel diameter 3.5 mm by quantitative coro-
nary angiography, likely equivalent to 3.8 mm by visual
estimate) did the late outcomes of optimal PTCA match
those of routine stenting. If an optimal balloon result is
obtained, PTCA may therefore be an attractive alternative
to stenting in large vessels, especially if other features are
present that weigh against stent implantation, such as
proximity of a large side branch that would be jailed.
Abciximab as an adjunct to PTCA or stenting provided
short-term clinical benefits in the CADILLAC trial, with a
reduction in 30-day ischemic TVR and subacute vessel
closure for both stent and PTCA patients, but had no
impact upon long-term mortality or ischemic TVR. When
abciximab utility was examined in patients achieving opti-
mal PTCA in this analysis, however, no significant early or
late benefits were seen, most likely because the presence of
an optimal angiographic PTCA result (low residual stenosis
without dissection) produced excellent short-term clinical
event rates, with a low rate of subacute thrombosis and
recurrent ischemia even without the glycoprotein IIb/IIIa
inhibitor.
In terms of cost-effectiveness, reduced initial hospitaliza-
tion costs with optimal PTCA were offset by the increased
expense of more frequent revascularization procedures dur-
ing the follow-up period, resulting in a cost-effectiveness
ratio for routine stenting versus optimal PTCA of $6,104
per repeat revascularization procedure avoided over the
one-year study period. This is similar to the cost-
effectiveness ratios seen for elective stenting versus PTCA
(approximately $10,000 per repeat revascularization
avoided) and brachytherapy for diffuse in-stent restenosis
(approximately $5,000 per repeat revascularization avoided)
(3,26).
Several limitations of this study should be noted. First,
this retrospective analysis was not pre-specified in the
original trial design and thus should be viewed as
hypothesis-generating rather than definitive. The optimal
study design would be a prospective trial in which patients
with AMI achieving stent-like PTCA results are then
randomized to stent versus no stent. Such a study, however,
is not likely to be performed, and the present analysis is the
largest investigation to date examining the benefits of
optimal PTCA relative to routine stent implantation in
AMI. Second, in the present intention to treat analysis, the
routine stent arm included patients in whom optimal PTCA
after pre-dilation was not achieved, and even some patients
in whom a stent was not implanted. These occurrences,
however, would have biased the results against the routine
stent arm, and thus make the conclusions favoring routine
stent implantation even stronger. Third, the definition of an
optimal PTCA (diameter stenosis 30% by quantitative
coronary analysis, equivalent to a visually estimated residual
stenosis of 10% to 20%) is one historically used by core
angiographic laboratories to define optimal PTCA (4,25),
and resulted in 40.7% of PTCA patients in this trial
meeting this criterion of an optimal result. Even when a
stricter definition of optimal PTCA was examined (core
laboratory diameter stenosis 20%, obtainable in only
12.3% of PTCA patients), routine stenting still provided
superior early and late outcomes. Intravascular ultrasound or
physiologic lesion assessment, though infrequently per-
formed during AMI intervention, may have better discrim-
inatory power than angiography to define an optimal PTCA
result. Fourth, by definition, final TIMI-3 flow was more
frequently present in optimal PTCA than routine stent
patients (100% vs. 95.7%, respectively, p  0.0001). Al-
though this did not translate into significantly greater
mortality among stented patients in this analysis, a larger
study population would be required to exclude this possi-
bility. Finally, patients in cardiogenic shock and saphenous
vein graft culprit vessels were excluded from randomization
in CADILLAC; whether these observations apply to these
subsets, or to patients undergoing elective PTCA, cannot be
stated with certainty.
In conclusion, when compared with “optimal” balloon
angioplasty in patients undergoing primary PCI for AMI,
routine stent implantation can be expected to further reduce
restenosis and enhance long-term freedom from repeat
hospitalization and revascularization.
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